Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2006

View Archived Issues

Merimepodib does not enhance ribavirin effects in hepatitis C

Obatoclax mesylate sensitizes cholangiocarcinoma cells to apoptosis

Novartis presents Q3 report

Raptor inlicenses Mesd reagents for treatment of cancer and osteoporosis

Ambit and Cephalon form kinase inhibitor collaboration

Novel hyaluronic acid binding peptide shows potential to prevent and treat wound infections

Parthenolide analogue LC-1 shows promising antitumor activity in preclinical studies

Dosing begins in phase IIb study of Tovaxin in MS

Trovax begins phase III trial in renal cancer

CYT009-GhrQb shows no effect on weight loss in obesity study

Maxy-alpha begins phase Ia study

Orphan drug designation for MORAb-009 in pancreatic cancer

Samaritan submits IND for Alzheimer's candidate caprospinol

Archimedes Pharma acquires Link Holdings

European orphan drug designation for Neuradiab in GBM

New crystalline form of ANA-975 studied in additional preclinical toxicology study

Avalon begins drug discovery program for survivin pathway

Lux licenses ciclosporin-eluting silicone matrix ocular implant from NIH

Melior signs research collaboration with Merck & Co.

IPI-504 shows promising biological activity in GIST

Mepact filed in E.U. for osteosarcoma

Avonex launched in Japan

Cyclacel and Roche report on the antitumor potential of new selective CDK inhibitors

Final phase I results and preclinical data on YM-155

Efficacy of DEBIO-025 in HIV/HCV co-infected patients

Novel 5-HT6 antagonist from Suven shows antiobesity properties in animal models

Recent Elan, Xenon and Gruenenthal patents disclose novel analgesic agents

Recent Tibotec and Trimeris patents report novel agents for HIV infection

Novel agents for cardiovascular disorders disclosed in recent patents